Related references
Note: Only part of the references are listed.Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
Paul G. Richardson et al.
BLOOD (2013)
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
Xavier Leleu et al.
BLOOD (2013)
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Alessandra Larocca et al.
BLOOD (2013)
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Paul G. Richardson et al.
BLOOD (2013)
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077
Wolfram Poenisch et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2013)
Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
Jacalyn Rosenblatt et al.
CLINICAL CANCER RESEARCH (2013)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
A. Z. Badros et al.
LEUKEMIA (2013)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij et al.
BLOOD (2012)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Suzanne Lentzsch et al.
BLOOD (2012)
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
Marta Chesi et al.
BLOOD (2012)
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
Don M. Benson et al.
BLOOD (2012)
Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma
Elisabeth Grey-Davies et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
Andrzej J. Jakubowiak et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
William Bensinger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
Ravi Vij et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
Melissa Alsina et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
Donna M. Weber et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
Sundar Jagannath et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
Andrzej J. Jakubowiak et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
N. W. C. J. van de Donk et al.
LEUKEMIA (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (vol 26, pg 149, 2012)
S. K. Kumar et al.
LEUKEMIA (2012)
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
Jeffrey L. Wolf et al.
LEUKEMIA & LYMPHOMA (2012)
200TH ANNIVERSARY ARTICLE Therapeutic Evolution and the Challenge of Rational Medicine
Jeremy A. Greene et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma
Irene M. Ghobrial et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM
Shirong Li et al.
BLOOD (2011)
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
Martha Q. Lacy et al.
BLOOD (2011)
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Simon J. Harrison et al.
BLOOD (2011)
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5
Yuan Xiao Zhu et al.
BLOOD (2011)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Monoclonal antibodies in the treatment of multiple myeloma
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease
Karthik Ramasamy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
Antonia Lopez-Girona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Ruben Niesvizky et al.
CANCER (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein
Craig C. Hofmeister et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
Irene M. Ghobrial et al.
LANCET ONCOLOGY (2011)
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
P. Moreau et al.
LEUKEMIA (2011)
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma
S. K. Martin et al.
LEUKEMIA (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
New Insights into Therapeutic Targets in Myeloma
Kenneth C. Anderson
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
Monica Galli et al.
ANNALS OF HEMATOLOGY (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
Maria Victoria Mateos et al.
CLINICAL CANCER RESEARCH (2010)
Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
A. K. Gandhi et al.
CURRENT CANCER DRUG TARGETS (2010)
Pleiotropic anti-myeloma activity of ITF2357: inhibition of interieukin-6 receptor signaling and repression of miR-19a and miR-19b
Katia Todoerti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
Mohamad Hussein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
The DAC system and associations with multiple myeloma
Enrique M. Ocio et al.
INVESTIGATIONAL NEW DRUGS (2010)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M. Q. Lacy et al.
LEUKEMIA (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Christine Galustian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
HDAC family: What are the cancer relevant targets?
Olaf Witt et al.
CANCER LETTERS (2009)
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
Laure Escoubet-Lozach et al.
CANCER RESEARCH (2009)
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros et al.
CLINICAL CANCER RESEARCH (2009)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
Han-Jie Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2009)
Dasatinib in relapsed or plateau-phase multiple myeloma
Tanya M. Wildes et al.
LEUKEMIA & LYMPHOMA (2009)
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
Sherif S. Farag et al.
LEUKEMIA RESEARCH (2009)
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy:: results of a Phase I clinical trial
Wolfram Poenisch et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
Matthew J. Streetly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
Enrique M. Ocio et al.
LANCET ONCOLOGY (2008)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson et al.
LEUKEMIA & LYMPHOMA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Ubiquitin receptors and ERAD: A network of pathways to the proteasome
Shahri Raasi et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2007)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Histone deacetylase inhibitors: Overview and perspectives
Milos Dokmanovic et al.
MOLECULAR CANCER RESEARCH (2007)
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
Laurence Catley et al.
BLOOD (2006)
Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins
Pedro Carvalho et al.
CELL (2006)
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
David H. Chang et al.
BLOOD (2006)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
Patricia Maiso et al.
CANCER RESEARCH (2006)
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone -: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)
W Pönisch et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
A phase II trial of imatinib in patients with refractory/relapsed myeloma
A Dispenzieri et al.
LEUKEMIA & LYMPHOMA (2006)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
M Alsina et al.
BLOOD (2004)
Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma
SB Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
CS Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
SA Schey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
D Gupta et al.
LEUKEMIA (2001)
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
B Barlogie et al.
BLOOD (2001)
Share Paper
